Jun 2026 (Q2 FY26) — Jul 29, 2026
Chemed Q2 FY26 — VITAS Outperforms, Roto-Rooter Navigates Marketing Headwinds
Read the full callChemed (CHE) earnings
- Jun 2026
- Jun 2026 (Q2 FY26)
- Dec 2025
Chemed earnings: last reported Wed, 29 Jul 2026, for the quarter ended Jun 2026.
Reported
The figures, each with its period
Each figure keeps its basis and period; nothing is filled in.
| Metric | Value | Change | Basis | Period | Note |
|---|---|---|---|---|---|
| Revenue | 673 | +8.8% YoY | Quarterly, as filed | Quarter to Jun 2026 | Revenue from operations as filed. |
| Operating margin | 13.3 | +2.3 pts YoY | Operating profit / revenue | Quarter to Jun 2026 | For the quarter; a change is in percentage points. |
| Net profit | 67.7 | +29.0% YoY | Quarterly, as filed | Quarter to Jun 2026 | Profit after tax as filed. |
Guidance
What management said, and what became of it
4 of 12 judged targets kept · 19 open · verdicts reflect calls analysed to Jun 2026.
| Target | Original wording | Said | Latest call | Verdict |
|---|---|---|---|---|
| Adjusted EPS | $23.25 to $24.25 | Dec 2025 | Based on the above full year 2026 earnings per diluted share excluding noncash expenses for stock options, tax benefits from stock option exercises, costs related to litigation and other discrete items, are estimated to be in the range of $25 to $25.75. | Revised Up |
| Effective tax rate (on adjusted earnings) | 24.5% | Dec 2025 | The revised 2026 guidance assumes an effective corporate tax rate on adjusted earnings of 24.5% and a diluted share count of 13.5 million shares. | On Track |
8 of CHEMED CORP's 31 targets were missed. See which ones, and which are quietly gone. The 2 above are the free sample; 29 more targets are in the full ledger.
Claimed
- VITAS average daily census (ADC) increased 6.1% year-over-year, exceeding 24,000 patients for the first time.
- VITAS admissions increased 9% year-over-year to 19,125, driven by both hospital and non-hospital sources.
- VITAS added $8.9 million to its Medicare cap cushion in the Florida combined program during the quarter.
- VITAS adjusted EBITDA (excluding Medicare Cap) increased 20.6% year-over-year to $80.6 million.
- Total Chemed revenue increased 8.8% and adjusted diluted EPS increased 41.9% in Q2 2026 compared to Q2 2025.
- Roto-Rooter commercial revenue increased 6.8% year-over-year, with branches having commercial business managers seeing a 13% increase.
Qualified
- Roto-Rooter's marketing spend increased by $3.1 million year-over-year due to a higher proportion of paid leads (59% of total leads vs. 54% in Q2 2025).
- Roto-Rooter's independent contractor revenue declined 1.9% in the quarter.
- Roto-Rooter's water restoration revenue declined 6.7% and average revenue per job declined 3.5% due to billing centralization disruption.
- Roto-Rooter's adjusted EBITDA margin declined 77 basis points year-over-year to 21.1%.
Price
$508.29 −0.80% · −$4.09
Performance +15.4% 1Y
1Y: $440.56 on 17 Oct 2025 → $508.29. High $552.72 (7 Aug 2026), low $368.59 (27 Mar 2026).
- Previous close
- $512.38
- 52-week range
- $368.59 – $552.72
- One year
- +14.24%
Overview
- Symbol
- CHE
- Sector
- Health Care
- Exchange
- US
- Currency
- USD
Guidance
What management said, and what became of it
4 of 12 judged targets kept · 19 open · verdicts reflect calls analysed to Jun 2026.
| Target | Original wording | Said | Latest call | Verdict |
|---|---|---|---|---|
| Adjusted EPS | $23.25 to $24.25 | Dec 2025 | Based on the above full year 2026 earnings per diluted share excluding noncash expenses for stock options, tax benefits from stock option exercises, costs related to litigation and other discrete items, are estimated to be in the range of $25 to $25.75. | Revised Up |
| Effective tax rate (on adjusted earnings) | 24.5% | Dec 2025 | The revised 2026 guidance assumes an effective corporate tax rate on adjusted earnings of 24.5% and a diluted share count of 13.5 million shares. | On Track |
Claimed
- VITAS average daily census (ADC) increased 6.1% year-over-year, exceeding 24,000 patients for the first time.
- VITAS admissions increased 9% year-over-year to 19,125, driven by both hospital and non-hospital sources.
- VITAS added $8.9 million to its Medicare cap cushion in the Florida combined program during the quarter.
- VITAS adjusted EBITDA (excluding Medicare Cap) increased 20.6% year-over-year to $80.6 million.
- Total Chemed revenue increased 8.8% and adjusted diluted EPS increased 41.9% in Q2 2026 compared to Q2 2025.
- Roto-Rooter commercial revenue increased 6.8% year-over-year, with branches having commercial business managers seeing a 13% increase.
Qualified
- Roto-Rooter's marketing spend increased by $3.1 million year-over-year due to a higher proportion of paid leads (59% of total leads vs. 54% in Q2 2025).
- Roto-Rooter's independent contractor revenue declined 1.9% in the quarter.
- Roto-Rooter's water restoration revenue declined 6.7% and average revenue per job declined 3.5% due to billing centralization disruption.
- Roto-Rooter's adjusted EBITDA margin declined 77 basis points year-over-year to 21.1%.
The full ledger
Open CHEMED CORP’s full ledger
A free account opens 5 company ledgers a month. All 31 tracked commitments, with each call’s wording and source.
Call summaries
Dec 2025 (Q4 FY25) — Feb 26, 2026
Chemed Q4 FY25 — VITAS Medicare Cap mitigated, Roto-Rooter faces billing and lead generation challenges
Read the full callEvery analysed call
Chemed earnings calls (CHE)
Financials
What the filings say
Net profit, year on year: +29% (quarter to jun 2026 against jun 2025).
| Line item | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 606 | 640 | 647 | 619 | 625 | 639 | 658 | 673 |
| Expenses | 514 | 526 | 552 | 551 | 550 | 539 | 573 | 584 |
| Operating profit | 92 | 114 | 95 | 68 | 75 | 101 | 85 | 89 |
| Operating margin | 15.2% | 17.8% | 14.7% | 11.0% | 12.0% | 15.7% | 12.9% | 13.3% |
| Other income | 9 | 7 | 1 | 3 | 9 | 5 | 5 | 4 |
| Interest | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 2 |
| Profit before tax | 101 | 120 | 96 | 71 | 84 | 105 | 89 | 91 |
| Tax rate | 25.0% | 24.8% | 25.0% | 26.2% | 23.1% | 27.2% | 25.4% | 25.9% |
| Net profit | 76 | 90 | 72 | 52 | 64 | 77 | 66 | 68 |
| EPS ($ per share) | 5.04 | — | 4.91 | 3.60 | 4.46 | — | 4.85 | 5.14 |
| Line item | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Equity capital | 35 | 36 | 36 | 37 | 37 | 37 | 37 | 38 |
| Reserves | 1,226 | 1,426 | 1,724 | 1,970 | 2,198 | 2,447 | 2,722 | 2,955 |
| Total liabilities | 384 | 542 | 534 | 719 | 643 | 560 | 550 | 559 |
| Fixed assets | 162 | 176 | 188 | 194 | 200 | 204 | 201 | 206 |
| Total assets | 976 | 1,268 | 1,435 | 1,343 | 1,442 | 1,668 | 1,669 | 1,538 |
| Line item | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Cash from operations | 287 | 301 | 489 | 309 | 310 | 330 | 417 | 388 |
| Cash from investing | -105 | -191 | -62 | -58 | -59 | -61 | -144 | -59 |
| Cash from financing | -188 | -109 | -271 | -381 | -209 | -80 | -359 | -433 |
| Capital expenditure | -53 | -53 | -59 | -59 | -57 | -57 | -50 | -63 |
| Free cash flow | 234 | 248 | 430 | 250 | 253 | 273 | 368 | 325 |
CHE revenue by segment
Segment Roto Rooter shrank from 37% to 34% of revenue over the last two years.
| Segment | Q3 FY2024 | Q4 FY2024 | Q1 FY2025 | Q2 FY2025 | Q3 FY2025 | Q4 FY2025 | Q1 FY2026 | Q2 FY2026 | YoY growth latest quarter |
|---|---|---|---|---|---|---|---|---|---|
| Segment Vitas | — | — | 63% | 64% | 65% | 66% | 64% | 66% | +11.9% |
| Segment Roto Rooter | 56% | 57% | 37% | 36% | 35% | 35% | 36% | 34% | +3.3% |
Share of consolidated revenue by quarter. Q4 is the fiscal year less its first three quarters.
See how segments are shifting across companies → Segment Shift
CHE operating KPIs by quarter
| KPI | Dec 2025 Q4 FY25 | Jun 2026 Q2 FY26 | Change vs prior quarter |
|---|---|---|---|
| Average daily census VITAS | 22.462KIn the fourth quarter of 2025, our average daily census was 22,462 patients, an increase of 1.3%.Source: earnings call transcript | 23.687KIn the second quarter of 2026, our average daily census was 23,687 patients.Source: earnings call transcript | +5.5% |
| Average length of stay VITAS | 115.1Our average length of stay in the quarter was 115.1 days.Source: earnings call transcript | 101.2Our average length of stay in the quarter was 101.2 days.Source: earnings call transcript | -12.1% |
| Median length of stay VITAS | 17Our median length of stay was 17 days in the fourth quarter of 2025, 1 day less than the median in the fourth quarter of 2024.Source: earnings call transcript | 16Our median length of stay was 16 days in the second quarter of 2026, a decline of 4 days from the second quarter of 2025.Source: earnings call transcript | -5.9% |
Operating figures the company stated on at least two of the calls shown, checked against each call's transcript. Click a figure to read the sentence. A dash means it was not stated that quarter.
Insider filings
50 filings between Nov 19, 2025 and Sep 30, 2026.
Open market
decisions to buy or sellPurchases
None
No insider bought shares.
Sales
$8.76M
13 sales by 5 insiders
Compensation
not trading decisions- 7
- Award — granted as compensation
- 17
- Option exercise — converted options into shares
- 11
- Tax withheld — shares kept back by the company to cover tax
Also filed: 2 gifts.
Who traded
open market only| Insider | Bought | Sold | Last filing |
|---|---|---|---|
| MCNAMARA KEVIN J | — | $7.27M | Sep 28, 2026 |
| LINDELL ANDREA R | — | $602.6K | Jun 9, 2026 |
| LEE SPENCER S | — | $541.0K | Aug 21, 2026 |
| WALSH GEORGE J III | — | $218.9K | May 29, 2026 |
| GRACE PATRICK P | — | $126.6K | Jul 31, 2026 |
Latest filings (50)
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| Sep 30, 2026 | LEE SPENCER S executive vice president | Option exercise | 12,099 | $5.39M |
| Sep 30, 2026 | LEE SPENCER S executive vice president | Tax withheld | 11,160 | $5.68M |
| Sep 28, 2026 | MCNAMARA KEVIN J president and CEO | Sale | 2,000 | $1.03M |
| Sep 28, 2026 | HUTTON THOMAS C vice president | Tax withheld | 4,270 | $2.16M |
| Sep 28, 2026 | HUTTON THOMAS C vice president | Option exercise | 4,629 | $2.06M |
| Sep 18, 2026 | MCNAMARA KEVIN J president and CEO | Sale | 2,000 | $1.00M |
| Aug 21, 2026 | MCNAMARA KEVIN J president and CEO | Sale | 2,000 | $1.08M |
| Aug 21, 2026 | LEE SPENCER S executive vice president | Sale | 1,000 | $541.0K |
| Aug 10, 2026 | Judkins Brian C VP and Chief Legal Officer | Tax withheld | 5,878 | $3.23M |
| Aug 10, 2026 | Judkins Brian C VP and Chief Legal Officer | Option exercise | 6,786 | $3.02M |
| Aug 5, 2026 | Wherley Joel L CEO - Vitas Healthcare | Tax withheld | 2,270 | $1.23M |
| Aug 5, 2026 | Wherley Joel L CEO - Vitas Healthcare | Option exercise | 2,599 | $1.16M |
| Aug 3, 2026 | MCNAMARA KEVIN J president and CEO | Sale | 2,000 | $1.08M |
| Jul 31, 2026 | MCNAMARA KEVIN J president and CEO | Option exercise | 2,001 | $891.1K |
| Jul 31, 2026 | MCNAMARA KEVIN J president and CEO | Tax withheld | 19,802 | $10.48M |
| Jul 31, 2026 | GRACE PATRICK P Director | Sale | 190 | $101.1K |
| Jun 9, 2026 | LINDELL ANDREA R Director | Sale | 1,347 | $602.6K |
| May 29, 2026 | WALSH GEORGE J III Director | Sale | 500 | $218.9K |
| May 18, 2026 | Heaney Christopher J Director | Award | 386 | $170.1K |
| May 18, 2026 | GRACE PATRICK P Director | Award | 386 | $170.1K |
| May 18, 2026 | DeLyons Ron Director | Award | 386 | $170.1K |
| May 18, 2026 | LINDELL ANDREA R Director | Award | 386 | $170.1K |
| May 18, 2026 | WALSH GEORGE J III Director | Award | 386 | $170.1K |
| May 18, 2026 | Mount John Meredith Jr. Director | Award | 386 | $170.1K |
| May 18, 2026 | McCarthy Eileen P Director | Award | 386 | $170.1K |
| May 8, 2026 | GRACE PATRICK P Director | Sale | 60 | $25.5K |
| May 1, 2026 | MCNAMARA KEVIN J president and CEO | Sale | 2,000 | $842.3K |
| Mar 27, 2026 | MCNAMARA KEVIN J president and CEO | Sale | 1,500 | $554.1K |
| Mar 12, 2026 | MCNAMARA KEVIN J president and CEO | Sale | 2,000 | $806.4K |
| Feb 13, 2026 | Witzeman Michael D VP & Chief Financial Officer | Option exercise | 0 | $0 |
| Feb 13, 2026 | Witzeman Michael D VP & Chief Financial Officer | Option exercise | 413 | $193.9K |
| Feb 13, 2026 | MCNAMARA KEVIN J president and CEO | Tax withheld | 1,192 | $559.7K |
| Feb 13, 2026 | MCNAMARA KEVIN J president and CEO | Option exercise | 0 | $0 |
| Feb 13, 2026 | MCNAMARA KEVIN J president and CEO | Option exercise | 2,714 | $1.27M |
| Feb 13, 2026 | Judkins Brian C VP and Chief Legal Officer | Option exercise | 0 | $0 |
| Feb 13, 2026 | Judkins Brian C VP and Chief Legal Officer | Tax withheld | 102 | $47.9K |
| Feb 13, 2026 | Judkins Brian C VP and Chief Legal Officer | Option exercise | 351 | $164.8K |
| Feb 13, 2026 | LEE SPENCER S executive vice president | Tax withheld | 154 | $72.3K |
| Feb 13, 2026 | LEE SPENCER S executive vice president | Option exercise | 0 | $0 |
| Feb 13, 2026 | Witzeman Michael D VP & Chief Financial Officer | Tax withheld | 120 | $56.3K |
| Feb 13, 2026 | LEE SPENCER S executive vice president | Option exercise | 499 | $234.3K |
| Feb 13, 2026 | HUTTON THOMAS C vice president | Tax withheld | 72 | $33.8K |
| Feb 13, 2026 | HUTTON THOMAS C vice president | Option exercise | 0 | $0 |
| Feb 13, 2026 | HUTTON THOMAS C vice president | Option exercise | 199 | $93.4K |
| Feb 13, 2026 | Wherley Joel L CEO - Vitas Healthcare | Tax withheld | 80 | $37.6K |
| Feb 13, 2026 | Wherley Joel L CEO - Vitas Healthcare | Option exercise | 0 | $0 |
| Feb 13, 2026 | Wherley Joel L CEO - Vitas Healthcare | Option exercise | 273 | $128.2K |
| Dec 26, 2025 | LINDELL ANDREA R Director | Gift | 463 | $0 |
| Nov 24, 2025 | MCNAMARA KEVIN J president and CEO | Sale | 2,000 | $875.1K |
| Nov 19, 2025 | LEE SPENCER S executive vice president | Gift | 60 | $0 |
Source: SEC Form 4 filings. Form 4 reports transactions, not the cap table — absence of filings says nothing about how much an insider owns, and a quiet window is not a signal.
Your own record
Start an Inve Case for CHEMED CORP
Free account. Everything above stays public.
Write why you follow CHEMED CORP and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.
Keep reading